Analysis of Polymorphisms in the Mediator Complex Subunit 13-like (Med 13L) Gene in the Context of Immune Function and Development of Experimental Arthritis by Sardar, Samra et al.
u n i ve r s i t y  o f  co pe n h ag e n  
Københavns Universitet
Analysis of Polymorphisms in the Mediator Complex Subunit 13-like (Med 13L) Gene in
the Context of Immune Function and Development of Experimental Arthritis
Sardar, Samra; Kanne, Katrine; Andersson, Asa
Published in:
Archivum Immunologiae et Therapiae Experimentalis
DOI:
10.1007/s00005-018-0516-8
Publication date:
2018
Document version
Publisher's PDF, also known as Version of record
Document license:
CC BY
Citation for published version (APA):
Sardar, S., Kanne, K., & Andersson, A. (2018). Analysis of Polymorphisms in the Mediator Complex Subunit 13-
like (Med 13L) Gene in the Context of Immune Function and Development of Experimental Arthritis. Archivum
Immunologiae et Therapiae Experimentalis, 66(5), 365-377. https://doi.org/10.1007/s00005-018-0516-8
Download date: 03. Feb. 2020
Vol.:(0123456789) 
Archivum Immunologiae et Therapiae Experimentalis (2018) 66:365–377 
https://doi.org/10.1007/s00005-018-0516-8
ORIGINAL ARTICLE
Analysis of Polymorphisms in the Mediator Complex Subunit 13-like 
(Med13L) Gene in the Context of Immune Function and Development 
of Experimental Arthritis
Samra Sardar1,2 · Katrine Kanne1,3 · Åsa Andersson1,4 
Received: 15 February 2018 / Accepted: 15 May 2018 / Published online: 27 June 2018 
© The Author(s) 2018
Abstract
The Mediator complex subunit 13-like (MED13L) protein is part of the multi-protein mediator complex and plays an 
important role in gene transcription. Polymorphisms in the MED13L gene have been linked to congenital heart anomalies 
and intellectual disabilities. Despite recent evidence of indirect links of MED13L to cytokine release and inflammation, 
impact of genetic variations in MED13L on immune cells remains unexplored. The B10.RIII and RIIIS/J mouse strains vary 
in susceptibility to induced experimental autoimmune disease models. From sequencing data of the two mouse strains, we 
identified six polymorphisms in the coding regions of Med13L. Using congenic mice, we studied the effect of these polymor-
phisms on immune cell development and function along with susceptibility to collagen-induced arthritis, an animal model 
for rheumatoid arthritis. Combining in vivo disease data, in vitro functional data, and computational analysis of the reported 
non-synonymous polymorphisms, we report that genetic polymorphisms in Med13L do not affect the immune phenotype in 
these mice and are predicted to be non-disease associated.
Keywords MED13L · THRAP2 · Mediator complex · Collagen-induced arthritis · Rheumatoid arthritis · Congenic mice
Introduction
The Mediator complex subunit 13-like (MED13L) protein, 
also known as thyroid hormone receptor associated protein 
2 (THRAP2) and Trap240-like (TRAP240L), is a recently 
identified molecule in humans (Musante et  al. 2004). 
MED13L is a paralog of the closely related protein called 
Mediator complex subunit 13 (MED13), and is believed 
to have arisen from gene duplication events (Daniels et al. 
2013). MED13L is one of the subunits of the dissociable 
CDK8 kinase module (CKM) of the Mediator, a multi-
protein complex that plays an essential role during RNA 
polymerase II (pol II) gene transcription (Sato et al. 2004; 
Tsai et al. 2014). The CKM, consisting of the CDK8, CYC-
LIN C, MED12/MED12L, and MED13/MED13L subunits, 
acts as a molecular switch that regulates the Mediator co-
activator function. The CKM associates with the Mediator 
to repress basal transcription of pol II-dependent genes and 
its dissociation from the Mediator has a stimulatory effect 
on transcription (Tsai et al. 2013). The MED13/MED13L 
subunit is critical for the CKM-dependent repression, as 
the strongest Mediator-CKM interaction involves a discrete 
contact through this subunit, thereby interfering with pol II 
recruitment and the holoenzyme formation (Knuesel et al. 
2009; Tsai et al. 2013).
Mutations in the MED13L gene have established cau-
sation of transposition of the great arteries, a congenital 
heart anomaly (Adegbola et al. 2015; Lei et al. 2014). More 
recently, a wider spectrum of diseases has been linked to 
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genetic variations in this gene and are collectively termed 
as MED13L haploinsufficiency syndrome, which is char-
acterized by cardiac anomalies, developmental delay, dis-
tinctive facial features, intellectual disability, and in some 
cases craniosynostosis (Adegbola et al. 2015; Yamamoto 
et al. 2017). However, presentation of the MED13L hap-
loinsufficiency syndrome varies among affected individu-
als, and not all patients have the associated cardiac pheno-
type (van Haelst et al. 2015). MED13L haploinsufficeinecy 
syndrome is a rare disease with only few cases reported 
worldwide (NIH rare diseases information database: https 
://rared iseas es.info.nih.gov/disea ses/12999 /med13 l-syndr 
ome#ref_11391 ). Therefore, the complete spectrum of dis-
eases associated with the syndrome and functional signifi-
cance of MED13L variants is not completely elucidated.
To date, 22 disease-associated mutations have been 
reported in the MED13L gene, but the molecular pathways 
affected by these mutations, leading to the reported clini-
cal phenotypes, are largely unknown (Musante et al. 2004; 
Yamamoto et al. 2017). MED13L has been reported to be 
involved in the Wnt, fibroblast growth factor (FGF), and 
retinoblastoma (Rb)/E2F pathways (Angus and Nevins 
2012; Asadollahi et al. 2017; Utami et al. 2014). The Wnt 
pathway is an evolutionarily conserved signaling pathway 
that controls proliferation and differentiation of progenitor 
cells and is critical for several biological processes. Emerg-
ing studies have highlighted not only developmental but 
also a regulatory role for the Wnt signaling pathway in the 
immune system (Clevers and Nusse 2012; Staal et al. 2008; 
van Amerongen and Nusse 2009). Rheumatoid arthritis (RA) 
is a chronic autoimmune disease characterized by inflamma-
tion in joints, followed by destruction of cartilage and bone. 
In studies of inflamed RA joint synovial tissue, it was shown 
that high amounts of Wnt isoforms were expressed (Sen 
et al. 2000). Similar findings were found in a mouse model 
for RA, collagen-induced arthritis (CIA), where Wnt5a was 
highly expressed in synovial tissue of arthritic mice (Maeda 
et al. 2012). Signaling through the FGR receptors 1–4 is 
another biological pathway where a role for MED13L is 
implicated. FGF has an important role in immunity, in par-
ticular through the neutrophil chemotactic function exerted 
by FGF1 and FGF2 (Haddad et al. 2011).
Although the Rb-E2F pathway is well known to have a 
crucial role in physiological proliferation and oncogenesis, 
its role in immune modulation is more recently appreciated. 
Rb impacts development of the immune system by regu-
lating various transcriptional pathways during progenitor 
differentiation, primarily common myeloid progenitors 
(Hutcheson et al. 2015).
Recent reports have also shown an indirect link of 
MED13L to inflammation, through activating transcrip-
tion factor 4 (ATF4). Tomppo et al. (2012) reported that 
MED13L is acting downstream of ATF4 that regulates 
its expression levels, thereby pointing towards potential 
involvement of MED13L in pathways regulated by ATF4. 
ATF4 is a member of the activating transcription factor 
family and is essential in many biological mechanisms, 
such as in the stress response, medullary hematopoiesis 
and bone resorption (Ameri and Harris 2008). Several 
studies show that ATF4 participates in inflammatory 
responses and positively regulates the secretion of pro-
inflammatory cytokines such as interleukin (IL)-6, IL-8 
and interferon γ (Iwasaki et al. 2014; Sasaki et al. 2017; 
Zhang et al. 2013). Furthermore, a genome-wide associa-
tion study (GWAS) suggested that a region in the proxim-
ity of the MED13L gene is associated with type 1 diabetes 
(Wellcome Trust Case Control Consortium 2007). Despite 
these reports on a potential role of MED13L in immune 
function and inflammation, the effect of genetic variations 
in this gene has not been studied in immune cells and ani-
mal models of autoimmune diseases.
Experimental animal models of RA are critical tools 
in furthering our understanding of disease pathogenesis, 
discovery of disease biomarkers, and in the development 
and testing of new therapies (Sardar and Andersson 2016). 
Among the available models, CIA is the most commonly 
used model. Based on its clinical and pathological simi-
larities to RA, in addition to its reproducibility, the CIA 
model has been used extensively to identify potential dis-
ease pathways, including the role of individual cell types 
and inflammatory mediators in disease onset and progres-
sion. CIA can be induced in susceptible strains of rodents 
(mouse and rat) (Holmdahl et al. 2002).
Congenic mice are inbred strains of mice where a spe-
cific genetic region from one mouse strain has been intro-
duced to a genetically different mouse strain by breeding. 
This breeding strategy, including selection- and back-
ground genotyping of each generation, makes it possible to 
study the role of naturally occurring polymorphisms for a 
particular phenotype and occupies a pivotal position in the 
elucidation of mechanisms in complex immune diseases 
such as RA (Rogner and Avner 2003).
In this study, we explored the effect of coding poly-
morphisms between two natural variants of the Med13L 
gene, found in the B10.RIII and RIIIS/J mouse strains that 
differ in their susceptibility to CIA and experimental auto-
immune encephalomyelitis (EAE), a model for multiple 
sclerosis. We used BR.RIIIS/J-Eae39r1 congenic mice that 
express the Med13L gene from the CIA and EAE resistant 
RIIIS/J donor strain on the genetic background of the B10.
RIII, which is susceptible to the experimental autoimmune 
disease models. We found that Med13L polymorphisms 
between the B10.RIII and RIIIS/J mouse strains do not 
affect immune phenotype, CIA development and autoan-
tibody production in these mice.
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Materials and Methods
Mice
BR.RIIIS/J-Eae39r congenic mice were produced by intro-
duction of the Eae39r fragment from the CIA resistant 
RIIIS/J donor strain, purchased from the Jackson Labora-
tory (Bar Harbor, ME, USA), to the CIA susceptible B10.
RIII background strain, provided by J. Klein (Tübingen, 
Germany), as previously described (Lindvall et al. 2009). 
The sub-congenic line, BR.RIIIS/J-Eae39r1, was produced 
by further inter-crossing heterozygous BR.RIIIS/J-Eae39r 
mice. All mice were kept and bred, under standard con-
ditions, in the animal facility at the Department of Drug 
Design and Pharmacology, Faculty of Health and Medical 
Sciences, University of Copenhagen, Denmark. Danish Ani-
mal Experiment Inspectorate license numbers: 2010/561-
1920 and 2015-15-0201-00794.
DNA Purification, Genotyping and Sequencing
Genomic DNA (gDNA) was purified from mouse ear or 
tail biopsies with a High Pure PCR template preparation 
kit (11796828001; Roche Holding AG, Basel, Switzerland) 
according to the manufacturer’s recommendation. Purified 
gDNA was used for genotyping by high resolution melt-
ing (HRM) single nucleotide polymorphism (SNP) geno-
typing for rs33583463 (5:118,596,773 bp, mouse genome 
assembly GRCm38) and by PCR-agarose gel electrophore-
sis method for homemade microsatellite marker D5tbxhm17 
(5:119,660,373 bp, mouse genome assembly GRCm38). 
HRM analysis was carried out on Roche LightCycler 480 
using High Resolution Melting Master (04909631001; 
Roche Holding AG, Basel, Switzerland) as described else-
where (Thomsen et al. 2012). Microsatellite marker genotyp-
ing was determined by analyzing PCR products on a Mega-
BACE1000 genotyping system (Amersham Biosciences, 
Little Chalfont, UK), as previously described (Karlsson et al. 
2003), or on a 3% agarose gel.
For DNA sequencing, all coding exons (and surround-
ing regions) of the Med13L gene for BR.RIIIS/J-Eae39r1 
congenic and B10.RIII control mice were amplified with 
specific primer pairs and sequenced by Sanger technology 
(GATC biotech, Germany). Primer sequences used for geno-
typing and sequencing are available upon request.
Bioinformatics
The identified SNPs between B10.RIII and BR.RIIIS/J-
Eae39r1 mice were coding synonymous, not changing the 
amino acid and non-synonymous, if the amino acid was 
altered. The possible effects of amino acid alteration by non-
synonymous variations were predicted by a web-based tool, 
sorting intolerant from tolerant (SIFT: http://siftd na.org/
www/SIFT_dbSNP .html). This tool identifies the impact of 
amino acid substitution on protein function and phenotype 
alterations based on the type of amino acid change and evo-
lutionary conservation of the position at which the change 
occurred, thereby distinguishing mutations more likely to 
be involved in disease (deleterious) from neutral (tolerated) 
polymorphisms (Ng and Henikoff 2003). It assigns scores 
to each residue, ranging 0–1, assuming that the most fre-
quent amino acid across species is being better tolerated. 
The SNPs with score between 0.0 and 0.05 are considered 
deleterious, and variants with score between 0.05 and 1.0 are 
predicted to be tolerated. Variants with scores very close to 
1.0 are more confidently predicted to be tolerated.
The orthologs of Med13L in closely related species were 
identified using the Ensembl database and evolutionary 
conservation of the regions around the amino acid changes 
in the protein was determined by multiple sequence align-
ment (MSA) by NCBI T-coffee server (http://www.ebi.ac.uk/
Tools /msa/tcoff ee/) (Di Tommaso et al. 2011). The results 
were imported into Jalview (Waterhouse et al. 2009) and 
SNP locations were marked.
Induction and Evaluation of Collagen‑Induced 
Arthritis
CIA was induced in 20 male mice, 8–10 weeks old, by intra-
dermal injection of 100 µg bovine collagen type II (CII-
7806; Sigma-Aldrich, St Louis, MO, USA) emulsified in 
incomplete Freund’s adjuvant (IFA) (F5506; Sigma-Aldrich, 
St Louis, MO, USA) at the base of the tail (day 0) followed 
by a booster dose of 50 µg bovine CII emulsified in IFA on 
day 35. Clinical disease was monitored in a blinded manner 
three times a week according to a scoring system whereby 
each inflamed toe (first phalanx excluded), all inflamed 
knuckles and inflamed wrist or ankle were assigned one 
point giving a maximum of 6 points per paw and a theo-
retical maximum score of 24 per mouse. According to the 
Danish Animal Experiment Inspectorate approved humane 
endpoints, mice receiving scores above 10 were euthanized.
Enzyme‑Linked Immunosorbent Assay 
for Anti‑collagen Antibody Titers
For anti-collagen type II enzyme-linked immunosorbent 
assay (ELISA), sera were prepared from blood collected on 
day 0 and 15 (by submandibular bleeding), and on the last 
day of CIA (by cardiac puncture). The levels of CII-specific 
IgM,  IgG1,  IgG2c and  IgG3 antibodies were determined as 
previously described (Lindvall et al. 2009). Briefly, serum 
dilutions were applied to 96-well micro-titer plates (163320; 
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Nunc maxisorp, Roskilde, Denmark) coated overnight 
with CII in phosphate buffered saline (PBS) (0.5 µg/well) 
and subsequently blocked with 1% bovine serum albumin 
(BSA)/PBS solution. The antigen–antibody binding signal 
was revealed by biotinylated secondary antibodies: goat 
anti-mouse IgM (1020-08),  IgG1 (1070-08),  IgG2c (1079-
08), and  IgG3 (1100-08) (SouthernBiotech, Birmingham, 
AL, USA) and horseradish peroxidase (HRP)-conjugated 
avidin (554058, BD Pharmingen, San Jose, CA, USA) fol-
lowed by detection with ABTS (2,2′-Azinobis [3-ethylben-
zothiazoline-6-sulfonic acid]-diammonium salt) substrate 
(A1888; Sigma-Aldrich, St Louis, MO, USA). A Spec-
traMax Microplate Reader (Molecular Devices Corporation, 
Sunnyvale, CA, USA) was used to read the absorbance at 
a wavelength of 405 nm with a wavelength correction set 
to 492 nm. Pooled sera from arthritic mice were used as a 
standard and the antibody levels were measured as arbitrary 
concentrations.
Preparation of Single‑Cell Suspension
Spleen and thymus were harvested, and single-cell suspen-
sions were prepared by mashing the tissue through a 40 µm 
cell strainer (431750; Corning, New York, USA). The spleen 
samples were treated with BD Lysing Buffer (555899; BD 
Biosciences, San Jose, CA, USA) to obtain erythrocyte-
free cell suspensions for cell cultures and flow cytometry. 
Single-cell suspensions of thymus were only used for flow 
cytometric analysis.
In Vitro Proliferation Assay of Splenic B and T 
Lymphocytes
Unsorted splenic lymphocytes (2 × 105 cells per well) were 
incubated in complete Dulbecco’s modified eagle’s medium 
consisting of DMEM GlutaMAX-I, 5% fetal bovine serum, 
1 mM Hepes, 50 µM 2-Mercaptoethanol, and 1% Penicil-
lin/Streptomycin (Invitrogen, Thermo Fisher Scientific, 
Waltham, MA, USA), and stimulated for 48 h with titrated 
amounts of lipopolysaccharide (LPS) (L2880; Sigma-
Aldrich, St Louis, MO, USA) or goat anti-mouse IgM 
F(ab′)2 (115-006-075; Jackson ImmunoResearch Laborato-
ries, Inc. Baltimore, PA, USA), for B lymphocyte prolifera-
tion assay. For measuring the T cell proliferative response, 
2 × 105 splenic lymphocytes were stimulated for 48 h with 
titrated amounts of Concanavalin A (ConA), or a combina-
tion of purified anti-mouse CD3 antibody, clone 145-2C11 
(550275; BD Biosciences, San Jose, CA, USA) and anti-
mouse CD28 antibody, clone 37.51 (16-0281; eBioscience, 
San Diego, CA, USA). The cells were pulsed with 1 µCi 
per well 3H-thymidine (Perkin Elmer, Waltham, MA, USA) 
for the final 16–18 h, and incorporation was counted on a 
TopCount Scintillation Counter (Perkin Elmer, Waltham, 
MA, USA). All data are shown as mean counts per minute, 
indicating 3H-thymidine incorporation, in triplicate cultures.
Measurement of IL‑2 in Culture Supernatants
The amounts of murine IL-2 in supernatant from spleno-
cyte cultures, stimulated with ConA or a combination of 
anti-CD3/anti-CD28 antibodies for 48 h, were determined 
by ELISA according to the manufacturer’s instructions (BD 
Pharmingen, San Diego, CA, USA). Briefly, 96-well micro-
titer plates were coated overnight with anti-mouse IL-2 cap-
ture antibody, clone JES6-1A12 (554424, BD Pharmingen, 
San Diego, CA, USA) in PBS (0.1 µg/well) and subsequently 
blocked with 1% BSA/PBS solution for 2 h. Then 100 µl of 
the culture supernatants, and doubling dilutions (0–7000 pg/
ml) of the mouse IL-2 standard (550069, BD Pharmingen, 
San Diego, CA, USA) were added to the wells and incu-
bated overnight. 0.05 µg/well of biotinylated IL-2 detection 
antibody clone JES6-5H4 (554424, BD Pharmingen, San 
Diego, CA, USA) for 1 h, followed by 1:1000 dilution of 
Avidin-HRP for 45 min at room temperature, and finally 
ABTS substrate were each applied to the wells. Absorbance 
was read at a wavelength of 405/nm and was converted to 
IL-2 concentration (pg/ml) using a linear standard curve.
Flow Cytometric Analysis
Single-cell suspensions of spleen and thymus tissue were 
prepared in complete DMEM medium as described above. 
Splenic lymphocytes were stained with anti-mouse CD4-
phycoerytherin (CD4-PE), anti-mouse CD8-phycoerytherin-
cyanine 5 (CD8-PE-Cy5), and anti-mouse CD19 fluores-
cein isothiocyanate antibodies, all purchased from BD 
Biosciences (San Jose, CA, USA) (Supplementary Fig. 1). 
Thymocytes were only stained with anti-mouse CD4-PE and 
anti-mouse CD8-PE-Cy5 antibodies to study various sub-
classes of T lymphocytes (Supplementary Fig. 2). 1 × 106 
cells were pre-incubated with 1 µg of Fc receptor block 
(anti-CD16/CD32 antibody clone 93; 14-0161-81, eBiosci-
ence, San Diego, CA, USA), prior to staining with 0.1 µg 
of respective antibodies for 15 min on ice. The stained cells 
were analyzed using Gallios Flow Cytometer (Beckman 
Coulter, Brea, CA, USA) and FlowJo software (Tree Star 
Inc, Ashland, OR, USA).
Statistical Analysis
Statistics were calculated in GraphPad Prism version 7.03. 
All CIA (except disease incidence and ethical survival data), 
ELISA, in vitro proliferation and flow cytometry data were 
calculated with Mann–Whitney U test. For CIA incidence 
and ethical survival data, Chi-square test and Fischer’s exact 
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test were applied, respectively. p values less than 0.05 were 
considered significant in all cases.
Results
Coding Polymorphisms in Med13L
The BR.RIIIS/J-Eae39r1 strain is genetically similar to 
B10.RIII except for the locus Eae39r1, which was intro-
duced from the RIIIS/J mouse strain. Eae39r1 comprises 
a small region with only two genetic elements, Gm15754 
and Med13l (Fig. 1). Gm15754 is a pseudogene, defined as 
genomic remnants of ancient protein-coding genes, and data 
on the functionality is controversial (Li et al. 2013; Tutar 
2012). Med13L is a protein-coding gene with 96% similarity 
to human MED13L.
Sequencing of coding regions of the Med13L gene from 
B10.RIII and BR.RIIIS/J-Eae39r1 mice, revealed six coding 
SNPs (Table 1). Two out of the six identified variants were 
coding non-synonymous, thereby leading to an alteration of 
the amino acid sequence of the protein product, while the 
rest were synonymous SNPs.
Comparison of the six SNPs in a number of laboratory 
mouse strains showed that the B10.RIII and RIIIS/J alleles 
are found in other mouse strains as well. The variations 
found in B10.RIII, shared with for example the C57Bl/6 and 
NOD mouse strains, are, however, less frequent (Table 2).
Analysis of Med13L Polymorphisms
Since rs13478486 and rs33215085 (Fig. 2) alter the amino 
acid sequence of the encoded protein, they were selected 
for further analysis. The SNP rs13478486 (E814D) changes 
glutamate (E) in B10.RIII to aspartate (D) in BR.RIIIS/J-
Eae39r1 mice. Both are hydrophilic (acidic) amino acids 
with similar structures, except for one extra methylene 
(–CH2) group in the side chain of glutamate that increases 
the molecular weight (mw) from 133 Dalton (Da) for aspar-
tate to 147 Da for glutamate. This extra carbon atom in glu-
tamate also changes the plane of symmetry for the amino 
acid to some extent, but its impact on the protein structure 
and function is context-dependent (Young and Ajami 2000).
Fig. 1  Genetic elements located in the Eae39r1 congenic frag-
ment on mouse chromosome 5. The region spans over 0.5 mega 
base pairs, whereby rs33731225 (5:118,442,102  bp) and rs6255362 
(5:118,985,914  bp), shown as thick lines, mark the boundaries of 
the fragment. The fragment consists of a pseudogene Gm15754 
(5:118,502,840–118,503,317) and a protein coding gene Med13L 
(5:118,560,719–118,765,435). Coordinates are based on Ensembl 
release 74 (mouse genome assembly GRCm38). The picture is a 
graphic depiction and not to scale
Table 1  List of SNPs in the 
coding region of Med13L in 
the B10.RIII and BR.RIIIS/J-
Eae39r1 strains of mice
a Coordinates according to Ensembl release 74 (mouse genome assembly GRCm38)
b Exon numbers are relative to the Med13l-201 transcript (length: 9296 bps, coding exons: 31, translation 
length: 2207 residues)
c Written as B10.RIII/ BR.RIIIS/J-Eae39r1; the altered nucleotides are shown in bold
d Functional class, CNSyn coding non-synonymous SNP, CSyn coding synonymous SNP
e E-glutamate, d-aspartate, l-leucine, V-valine, I-isoleucine, A-alanine, G-glycine, P-proline
Variation ID Locationa Exonb Codonc Functional  classd Amino acid 
 changee
Residue
rs13478486 5:118,731,440 13 GAA/GAC CNSyn E/D 814
rs38736382 5:118,742,369 17 CTC/CTT CSyn L 1175
rs33215085 5:118,742,508 17 GTA/ATA CNSyn V/I 1222
rs33658171 5:118,742,588 17 GCC/GCT CSyn A 1248
rs36568864 5:118,745,106 18 GGC/GGT CSyn G 1343
rs33709896 5:118,748,751 21 CCC/CCT CSyn P 1572
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The other SNP, rs33215085 (V1222I), replaces valine (V) 
in B10.RIII with isoleucine (I) in BR.RIIIS/J-Eae39r1 mice. 
Both valine (mw: 117 Da) and isoleucine (mw: 131 Da) are 
non-polar hydrophobic amino acids that participate in hydro-
phobic interactions and determine the tertiary structure of 
the protein. Although their structure only varies by the pres-
ence of one extra methyl (–CH3) group in isoleucine, altered 
function (ligand selectivity) was reported for a protein where 
V was substituted by I (Yuan et al. 2010).
Taken together, the amino acid substitutions between 
B10.RIII and BR.RIIIS/J-Eae39r1 mice, as a result of 
rs13478486 and rs33215085, do not change the chemical 
properties of the protein to a large extent, and may not affect 
the three-dimensional structure and stability of the protein.
SIFT Prediction and Evolutionary Conservation 
of Med13L Mutation Sites
It has previously been reported that disease-associated muta-
tions are more likely to occur in functionally important 
regions of proteins that are evolutionary conserved (Mooney 
and Klein 2002; Mooney 2005). To investigate the evolution-
ary conservation of the regions with identified amino acid 
alterations in Med13L, MSA was performed with closely 
related species. We found that the region around E814D is 
more conserved than V1222I (Fig. 3), and that the nature 
of amino acid substitutions at these positions is not unique 
but observed naturally in some closely related orthologs. 
These findings indicate that amino acid variations caused 
by rs13478486 and rs33215085 are present in some other 
organisms and are less likely to be disease-related mutations. 
This goes in line with our SIFT predictions for rs13478486 
(score 0.32) and rs33215085 (score 0.46) indicating that 
both variations are likely to be tolerable and non-disease 
causing.
Med13L Polymorphisms Do Not Affect Development 
of CIA and Anti‑CII Antibody Titers
Considering the putative role of Med13L in autoimmun-
ity, we studied the in vivo effect of the identified Med13L 
SNPs in the CIA mouse model. Upon induction of arthritis 
with CII/IFA, we found that both B10.RIII and BR.RIIIS/
J-Eae39r1 congenic mice developed progressive arthritis 
over the trial period and that there was no significant dif-
ference in disease onset, incidence, and severity between 
the groups (Fig. 4a; Table 3). Moreover, anti-CII antibody 
levels, measured during the pre-clinical phase (day 15) 
and late clinical phase (day 72), were comparable in both 
groups of mice (Fig. 4b, c). Taken together, both B10.RIII 
and BR.RIIIS/J-Eae39r1 mice developed progressive CIA 
with corresponding rise in anti-CII antibodies of different 
Table 2  Allelic variation in the 
coding region of Med13L 
a Seven common laboratory mouse strains were compared to the B10.RIII and RIIIS/J parental strains 
(http://www.ensem ble.org)
b Variant ID
c Minor allele frequencies (MAF) are based on data from the Mouse Genome Project (http://www.sange r.ac.
uk/scien ce/data/mouse -genom es-proje ct)
Mouse  straina rs1347848b 
MAF: 0.22c
rs38736382 
MAF: 0.39
rs33215085 
MAF: 0.33
rs33658171 
MAF: 0.39
rs36568864 
MAF: 0.39
rs33709896 
MAF: 0.39
B10.RIII A/A C/C G/G C/C C/C C/C
RIIIS/J C/C T/T A/A T/T T/T T/T
129S1/SvImJ C/C T/T A/A T/T T/T T/T
A/J C/C T/T A/A T/T T/T T/T
BALB/cJ C/C T/T A/A T/T T/T T/T
C3H/HeJ C/C T/T A/A T/T T/T T/T
C57BL/6NJ A/A C/C G/G C/C C/C C/C
DBA/2J C/C T/T A/A T/T T/T T/T
NOD/ShiLtJ A/A C/C G/G C/C C/C C/C
Fig. 2  Graphical presentation of the Med13L protein and amino 
acid-altering SNPs between B10.RIII and BR.RIIIS/J-Eae39r1 mice. 
The conserved N terminal (Med13l_N) and C terminal (Med13l_C) 
domains are shown in grey. Numbers representing amino acid residue 
and location of amino acid changes due to coding non-synonymous 
SNPs between B10.RIII and BR.RIIIS/J-Eae39r1 mice (E814D and 
V1222I) are shown by arrows
371Archivum Immunologiae et Therapiae Experimentalis (2018) 66:365–377 
1 3
Fig. 3  Protein sequence align-
ment across species performed 
by the T-coffee webtool. The 
regions flanking rs13478486-
E814D (a) and rs33215085-
V1222I (b) were aligned to 
Med13L orthologs in human, 
chimpanzee, guinea pig, mon-
key, cow and rat. The sequence 
identifier is written as Uniprot 
id of protein_Biological name 
of organism_common name of 
organism
Fig. 4  Collagen-induced arthritis (CIA) development and progres-
sion in B10.RIIIS/J-Eae39r1 mice in comparison to B10.RIII lit-
termate control mice, represented as mean arthritis score for each 
group ± standard error of the mean (SEM) (a); IgM (b) and IgG (c) 
anti-collagen type II antibody responses in early pre-clinical CIA, 
measured on day 15, and late clinical CIA, measured on day 72. 
(n = 9 for B10.RIIIS/J-Eae39r1 and n = 11 for B10.RIII)
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isotypes, indicating that Med13L SNPs do not influence 
CIA susceptibility and autoantibody response in these 
mice upon immunization.
Med13L Polymorphisms Do Not Affect Lymphocyte 
Development and Function
We further sought to examine the effect of the Med13L 
SNPs in lymphoid cell lineage development and function 
that might be of importance for other immune-mediated 
disorders. Therefore, we characterized the lymphocyte 
populations in naïve B10.RIII and BR.RIIIS/J-Eae39r1 
mice by flow cytometry. The ratio between the splenic 
B- and T-cell fractions was found decreased in BR.RIIIS/
J-Eae39r1 mice (p = 0.0571). This could be due to a 
decreased relative number of B cells and a slightly 
increased proportion of T cells, but no significant differ-
ence in the proportion of B cells, T cells,  CD4+ and  CD8+ 
T cells in spleen was observed (Table 4). Furthermore, the 
proportion of thymocyte subpopulations was comparable 
between B10.RIII and BR.RIIIS/J-Eae39r1 mice, suggest-
ing that the Med13L polymorphisms have no large effect 
on B and T lymphocyte development.
Table 3  Collagen-induced 
arthritis (CIA) diseases 
phenotypes in B10.RIII and 
BR.RIIIS/J-Eae39r1 mice
a Statistics were calculated using Chi-squared test for incidence and number of mice euthanized and Mann–
Whitney U test for the other parameters
b Mean max score, indicating CIA severity, is the mean (± SEM) of the maximum score for all affected 
mice in the group
c Area under curve (AUC) is the mean (± SEM) of the sum of scores for mice of the corresponding geno-
type (day 28–72)
d Mice having a score above 10 were euthanized during the experiment as per recommendations of animal 
welfare authorities
Disease phenotype BR.RIIIS/J-Eae39r1 con-
genic (n = 9)
B10.RIII littermate con-
trols (n = 11)
p  valuea
Incidence 5/9 (55.6%) 10/11 (90.9%) 0.413
Mean max  scoreb 6.7 ± 2.2 7.4 ± 1.5 0.749
AUC c 99.1 ± 33.6 110.3 ± 24.7 0.599
Mean day of disease onset 30.2 ± 1.4 26.1 ± 3.5 0.582
Number of euthanized  miced 5/9 (55.6%) 6/11 (54.5%) 0.964
Table 4  Flow cytometry 
profiles of splenocytes and 
thymocytes from B10.RIII and 
BR.RIIIS/J-Eae39r1 mice
a p-values were calculated with Mann-Whitney U test
b Data represent relative numbers (%) of B lymphocytes, T lymphocytes (measured as the sum of  CD4+ and 
 CD8+ T-cells),  CD4+ and  CD8+ T lymphocytes and ratio of B to T lymphocytes in spleen, and  CD4+CD8+ 
double positive (DP),  CD4+CD8- and  CD4-CD8+ single positive (SP) and  CD4-CD8- double negative (DN) 
thymocytes.
c Data are presented as mean ± SEM for each group where n=4
Spleen
B10.RIII BR.RIIIS/J-Eae39r1 p-valuea
CD19+ B cells (%)b 51.3 ± 2.4c 46 ± 1.4 0.200
T cells (%) 23.2 ± 3.3 29.2 ± 1.4 0.343
CD4+ T cells (%) 13.7 ± 1.9 17 ± 0.9 0.314
CD8+ T cells (%) 9.5 ± 1.4 12.2 ± 0.7 0.343
B/ T cell ratio 2.3 ± 0.3 1.6 ± 0.1 0.057
Thymus
B10.RIII BR.RIIIS/J-Eae39r1 p-value
CD4+  CD8+ T cells (%) 63.6 ± 4.5 57.1 ± 8.9 0.486
CD4+  CD8- T cells (%) 3.9 ± 0.2 3.0 ± 0.4 0.171
CD4-  CD8+ T cells (%) 1.2 ± 0.1 1 ± 0.1 0.542
CD4-  CD8- T cells (%) 28.6 ± 4.4 36.3 ± 9.6 0.486
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To determine whether the Med13L polymorphisms 
would influence lymphocyte activation, the prolifera-
tive response of in vitro stimulated splenic lymphocytes 
from naïve B10.RIII and BR.RIIIS/J-Eae39r1 mice was 
analyzed. No difference in proliferation of B cells upon 
stimulation with either LPS or anti-IgM was observed 
(Fig. 5a, b). Furthermore, no difference in proliferation 
or IL-2 production by T cells, following stimulation 
with ConA or anti-CD3/CD28 antibodies, was observed 
when comparing BR.RIIIS/J-Eae39r1 mice with B10.
RIII littermate controls (Fig. 5c–f). These data suggest 
that the Med13L polymorphisms between B10.RIII and 
Fig. 5  In vitro proliferative responses of splenic B and T lymphocytes 
from B10.RIII and BR.RIIIS/J-Eae39r1 mice. 3H-thymidine incorpo-
ration, represented as counts per minute ± SEM, of B cells following 
in vitro stimulation with: (a) titrated concentrations (0–10 µg/ml) of 
LPS; (b) titrated concentrations (0–60  µg/ml) of anti-IgM antibody. 
3H-thymidine incorporation of  CD4+ T cells following in vitro stimu-
lation with: (c) titrated concentrations (0–1.25 µg/ml) of ConA; (d) a 
combination of titrated concentrations (0–3 µg/ml) of anti-CD3 anti-
body and fixed concentration of anti-CD28 antibody (3 µg/ml). (e, f) 
IL-2 production (mean ± SEM) in the supernatant of T cells stimu-
lated with ConA or anti-CD3/CD28 antibodies
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BR.RIIIS/J-Eae39r1 have no effect on numbers and activ-
ity of B- and T lymphocytes.
Discussion
MED13L is an important component of the Mediator com-
plex, responsible for bridging the RNA pol II enzyme and 
transcription factors to initiate transcription of protein-cod-
ing genes and non-coding RNA genes (Poss et al. 2013). 
MED13L is an evolutionarily conserved gene and the 
encoded protein share about 96% similarity with the mouse 
ortholog (Musante et al. 2004). Polymorphisms in this gene 
have been associated with cardiac and neurological pheno-
types in humans (van Haelst et al. 2015; Yamamoto et al. 
2017). However, the complete spectrum of diseases associ-
ated with MED13L polymorphisms and significance of these 
variations in relation to molecular pathways, are yet to be 
identified.
Based on reports that MED13L is involved in Wnt, FGF, 
Rb/E2F and ATF4 related pathways that play critical roles 
in lymphocyte development and function, in addition to 
inflammatory responses (Ameri and Harris 2008; Asadol-
lahi et al. 2017; Clevers and Nusse 2012; Hutcheson et al. 
2015; Kitajima and Takahashi 2017; Markey et al. 2007; 
Staal et al. 2008; Tomppo et al. 2012; van Amerongen and 
Nusse 2009; Zhang et al. 2013), we studied Med13L poly-
morphisms in the context of immune cell activation and 
pathogenesis of RA, a chronic inflammatory autoimmune 
disorder. From recent CIA studies, where mice with larger 
congenic fragments, including Med13L, developed signifi-
cantly more severe arthritis (unpublished data), we wanted to 
investigate whether coding polymorphisms in Med13L might 
affect the disease phenotype, and/or development and func-
tion of lymphocytes involved in immune pathogenesis of the 
disease (Holmdahl et al. 2002; Sardar and Andersson 2016). 
Through extensive breeding and testing of congenic mice, 
BR.RIIIS/J-Eae39r1 mice were established carrying only 
a 0.5 Mega base pair congenic fragment from the RIIIS/J 
strain, in which the only protein-coding gene is Med13L 
(Fig. 1). This makes these mice more valuable than knock-
out mice in terms of standardized genetic-background effects 
and ability to dissect out the effects of a particular allele(s) 
with natural variation (Rogner and Avner 2003).
MED13L has been shown to be involved in the Wnt 
and Rb/E2F signaling pathways (Angus and Nevins 2012; 
Utami et al. 2014) and the importance of Wnt signaling in 
T- and B-cell development in thymus and bone marrow, 
respectively, and their peripheral activation, is underpinned 
by a number of in vivo and in vitro studies. The thymi of 
mice deficient in Wnt (1 and 4) proteins show decreased 
number of mature  CD4+ and  CD8+ T cells (Mulroy et al. 
2002), while activation of the Wnt pathway in transgenic 
mice, overexpressing activated forms of β-catenin, led to 
the generation of more thymocytes (Mulroy et al. 2003). 
Moreover, in vitro inhibition of Wnt proteins in fetal thymo-
cyte cultures inhibits thymocyte differentiation (Staal et al. 
2001). B-cell progenitors in bone marrow also express Wnt 
genes at various developmental stages and culturing mouse 
fetal pro-B cells in Wnt protein (3A)-conditioned medium 
leads to increased proliferation (Reya et al. 2000). Addition-
ally, reduced numbers of  CD19+ B lymphocytes in bone 
marrow and periphery have been observed with transgenic 
expression of a canonical Wnt inhibitor, kallistatin (McBride 
et al. 2017). In accordance with this, defects in T- and B-cell 
development in mice deficient for the Wnt-responsive tran-
scription factors TCF1 and LEF1 are observed (Okamura 
et al. 1998; Reya et al. 2000). Furthermore, Markey et al. 
(2007) demonstrated that the deficiency of Rb protein in 
adult fibroblast cells is associated with down-regulation 
of genes involved in immune functions, with concomitant 
up-regulation of cell cycle genes thereby highlighting that 
Rb lies at the crossroads of proliferation and the immune 
response. It has been proposed that Rb directly regulates pro-
inflammatory signaling and its inactivation has been associ-
ated with increased levels of pro-inflammatory cytokines, 
including chemokine (C-X-C motif) ligand 1 and 2 and IL-8 
(Kitajima and Takahashi 2017). Thus, it is reasonable to 
expect that MED13L would be important for diseases within 
the immune system and for having modulating effects in the 
immune response.
We identified six SNPs in the coding region of Med13L, 
when comparing the genomic sequence of B10.RIII and 
BR.RIIIS/J-Eae39r1 mice, and studied the SNPs putative 
functional effects on CIA development and immune cell 
activity, in addition to computational analysis. As synony-
mous SNPs are more likely to be neutral and tolerable in 
nature (Vitkup et  al. 2003), our computational analysis 
and comparison of allelic variations in common labora-
tory mouse strains focused on the non-synonymous SNPs 
rs13478486 (E814D) and rs33215085 (V1222I). E814D cor-
responds to position 819 in the human protein and data on 
disease associated SNPs shows that it lies in a cluster with 
four known mutations S747Y, P835L, R842, D860G that are 
associated with mild to severe MED13L haploinsufficiency 
syndrome (Asadollahi et al. 2017). While the significance of 
these variants is uncertain, D860G is predicted to affect the 
secondary structure of MED13L. Patients with these muta-
tions did not have any reported immune phenotypes, which 
goes in favor of our findings. However, these studies did not 
follow-up the patients over a long time so the possibility of 
later-onset immune mediated diseases cannot be excluded. 
V1222I corresponds to position 1223 in the human protein 
and a coding SNP rs748598145 (I1223M) has been reported 
for humans, but with no associated phenotype (NCBI SNP 
database: https ://www.ncbi.nlm.nih.gov/SNP/).
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Comparison between the two SNPs showed that V1222I 
has higher SIFT score and less conservation at the site of 
amino acid change than E814D, indicating that V1222I is 
more likely to be benign in nature, among the two variants 
under consideration. This finding is intriguing as V1222I 
lies at the minus 2-position of a LxxLL motif in both mouse 
and human protein. LxxLL motifs are present in many 
transcription factors and cofactors including components 
of the Mediator complex (Chen and Roeder 2011). These 
participate in many protein–protein interactions associated 
with different aspects of transcriptional regulation and have 
recently been implicated in various leukemias. The amino 
acids surrounding LxxLL motif are proposed to affect the 
binding affinity of these interactions and can alter the func-
tion of the protein (Plevin et al. 2005). On the contrary, we 
found that V1222I does not affect the function of Med13L 
in relation to immune phenotype and CIA development 
in BR.RIIIS/J-Eae39r1 mice. This could be explained by 
chemical and structural similarities between valine and iso-
leucine, as reflected in the benign prediction of SIFT score 
for the amino acid switch.
MED13L has a putative link to RA pathogenesis through 
the Wnt and FGF pathways (Malemud 2007, 2013; Ye et al. 
2015) and in a GWAS including RA patients and healthy 
controls from Korea, the homologous Eae39r region on 
human chromosome 12, including the MED13L gene, was 
weakly associated (Freudenberg et al. 2011).
Therefore, we used the classical CIA experimental model 
of RA to study the in vivo effects of Med13L polymor-
phisms. We have demonstrated that mice carrying reported 
Med13L SNPs develop CIA and mount an anti-collagen 
type II autoantibody response to the same extent as their 
non-mutant littermate controls upon induction with CII. 
Although a trend towards lower B to T lymphocyte ratio 
was observed in BR.RIIIS/J-Eae39r1 mice, the difference 
was not significant and did not affect development of auto-
immune arthritis in these mice. One emerging question is 
whether the polymorphisms found in the Med13L gene could 
have implications for disease development in other arthritis 
models like the KBxN serum-transfer arthritis model, the 
SKG model, and for CIA in the DBA/1 strain. The genetic 
background of KBxN is a cross between the C57Bl/6 and 
NOD mouse strains (Kouskoff et al. 1996), which both share 
the same alleles as B10.RIII in the Eae39r1 locus (Table 2). 
The original SKG strain has the BALB/c genetic background 
(Sakaguchi et al. 2003), which share the RIIIS/J alleles in 
Eae39r1. Since we do not find any differences in arthritis 
susceptibility between mice with B10.RIII background and 
different alleles in the Eae39r1 locus, we find it unlikely 
that the polymorphisms in Med13L would influence disease 
development in other arthritis susceptible strains. Concern-
ing DBA/1, which is a commonly used mouse strain for CIA 
studies (Holmdahl et al. 1989; Trentham 1982), the map 
of SNPs in different databases is not as comprehensive as 
for other mouse strains. For one of the SNPs in Med13L 
(rs13478486), DBA/1 has the same allele as DBA/2 (http://
www.infor matic s.jax.org/snp/ and Table 2), which makes it 
likely that DBA/1 carries the same alleles as DBA/2 in the 
whole locus and would be similar to RIIIS/J. Our conclusion 
from the results of our present investigation is that Med13L 
is not of crucial importance for disease development in CIA, 
but to make a final conclusion, the polymorphisms would 
need to be inferred in other arthritis susceptible strains and 
be tested for arthritis development in this context.
To summarize, we propose that the amino acid substi-
tutions caused by rs13478486 (E814D) and rs33215085 
(V1222I) variations in Med13L, do not affect arthritis devel-
opment in the CIA model and lymphocyte development and 
function in general, and are less likely to be associated with 
immune-related diseases.
Conclusion
In studies of Eae39r1 congenic mice, we have shown that 
coding polymorphisms in the Med13L gene does not influ-
ence the function of the Med13L protein in terms of immune 
phenotype. We conclude that the investigated natural poly-
morphisms in Med13L do not play a critical role in auto-
immune arthritis development, lymphocyte numbers or 
function. However, the role for Med13L in other inflamma-
tion- and autoimmunity-related pathways warrants further 
investigation.
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